Company Overview of Polyphor Ltd
Polyphor Ltd. is a pharmaceutical company that focuses on the discovery and development of macrocycle drugs addressing unmet medical needs. Its products include POL6326, an antagonist of the chemokine receptor CXCR4 for stem cell transplantation, tissue repair, and combination treatments in oncology; POL7080, a pseudomonas specific antibiotic with a mode of action to treat pseudomonas infections; and POL6014, an inhaled inhibitor of human neutrophil elastase for the treatment of Alpha-1 antitrypsin deficiency, cystic fibrosis, and other lung diseases. The company also develops solutions for multiple myeloma. Its pipeline of macrocycles also targets leukemia and chronic obstructive pulmonary ...
Founded in 1996
Key Executives for Polyphor Ltd
Co-Founder and Chief Scientific Officer
Head of Technology Platforms
Compensation as of Fiscal Year 2014.
Polyphor Ltd Key Developments
Polyphor Ltd Presents at UBS Global Healthcare Conference, May-21-2014 12:00 PM
Mar 19 14
Polyphor Ltd Presents at UBS Global Healthcare Conference, May-21-2014 12:00 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Jean-Pierre Obrecht, Co-Founder, Chief Executive Officer and Director.
Roche Joins Forces with Polyphor to Develop an Antibiotic
Jan 11 14
Roche announced that it had joined forces with Polyphor to develop an antibiotic to fight a superbug that is increasing disease as per recorded by the hospitals. The contract is signed by Roche regarding an exclusive worldwide licensing with Polyphor to develop and commercialise the latter's experimental antibiotic POL7080. The drug's target is the Pseudomonas aeruginosa bacteria, which can give rise to life-threatening infections and usually occurs in patients in hospital, as well as members of the broader public who have weakened immune systems. Pseudomonas aeruginosa accounts for one in every 10 hospital-acquired infections in the United States and is listed as one of the six most dangerous drug-resistant microbes. This disease is mainly caused at urinary tract, respiratory system, joints and bones, and digestive system. The disease is a major hazard for patients suffering with cancer, AIDS, severe burns, and chronic infections such as cystic fibrosis.
Polyphor Signs License Agreement with Roche
Nov 5 13
Polyphor Ltd. and Roche Holding Ltd. have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor's investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa. Both the companies are based in Switzerland. Under the terms of the agreement, Roche will make an upfront payment of CHF 35 million ($38.38 million) to Polyphor as well as payments upon reaching certain development, regulatory and commercial milestones, potentially up to CHF 465 million ($509.95 million). In addition, Polyphor is entitled to receive tiered double-digit royalties on product sales. Polyphor will retain the option to co-promote an inhaled formulation of POL7080 in Europe. The value of the deal was $548.33 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|